Ye Jinzhou, Chen Xinhai
Institute of Infectious Diseases, Shenzhen Bay Laboratory, Shenzhen 518132, China.
Antibiotics (Basel). 2022 Dec 30;12(1):67. doi: 10.3390/antibiotics12010067.
Infections caused by antibiotic-resistant bacteria (ARB) are one of the major global health challenges of our time. In addition to developing new antibiotics to combat ARB, sensitizing ARB, or pursuing alternatives to existing antibiotics are promising options to counter antibiotic resistance. This review compiles the most promising anti-ARB strategies currently under development. These strategies include the following: (i) discovery of novel antibiotics by modification of existing antibiotics, screening of small-molecule libraries, or exploration of peculiar places; (ii) improvement in the efficacy of existing antibiotics through metabolic stimulation or by loading a novel, more efficient delivery systems; (iii) development of alternatives to conventional antibiotics such as bacteriophages and their encoded endolysins, anti-biofilm drugs, probiotics, nanomaterials, vaccines, and antibody therapies. Clinical or preclinical studies show that these treatments possess great potential against ARB. Some anti-ARB products are expected to become commercially available in the near future.
由抗生素耐药菌(ARB)引起的感染是我们这个时代全球主要的健康挑战之一。除了开发新的抗生素来对抗ARB外,使ARB敏感化或寻求现有抗生素的替代品也是应对抗生素耐药性的有前景的选择。本综述汇编了目前正在开发的最有前景的抗ARB策略。这些策略包括:(i)通过修饰现有抗生素、筛选小分子文库或探索特殊场所来发现新型抗生素;(ii)通过代谢刺激或加载新型、更高效的递送系统来提高现有抗生素的疗效;(iii)开发传统抗生素的替代品,如噬菌体及其编码的内溶素、抗生物膜药物、益生菌、纳米材料、疫苗和抗体疗法。临床或临床前研究表明,这些治疗方法对ARB具有巨大潜力。一些抗ARB产品有望在不久的将来上市。